Methods and compositions for interferon therapy

• US 20040014709A1
• Filed: 06/04/2003
• Published: 01/22/2004
• Est. Priority Date: 01/08/1996
• Status: Abandoned Application

• Current Assignee: Canji Inc. (Merck & Co., Inc.)
• Original Assignee: Canji Inc. (Merck & Co., Inc.)
• Inventors: Engler, Heidrun, Nagabhushan, Tattanahalli L., Youngster, Stephen
• Application Number:
  US10/455,215
• Publication Number:
  US 20040014709A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 38/1709 from mammals
• CPC Class Codes: A61K 47/10 Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• CPC Class Codes: A61K 47/186 Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: C07K 14/4736 Retinoblastoma protein
• CPC Class Codes: C07K 14/4746 p53
• CPC Class Codes: C12N 15/87 Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
• CPC Class Codes: C12N 2799/022 where the vector is derived from an adenovirus

Abstract

Methods and pharmaceutical compositions for administering interferon therapy to tissues or organs having an epithelial cell layer are provided. A recombinant adenoviral vector encoding an interferon gene is administered to the target tissue or organ in combination with treatment with a delivery enhancing agent which increases the transduction of the cells of the target tissues or organs by the vector. The methods and combinations are useful in the treatment of cancers and other conditions responsive to interferon therapy. An exemplary method comprises the transurethral intravesical administration to the bladder of a therapeutically effective amount of a pharmaceutical composition comprising an adenoviral vector encoding alpha-interferon and SYN3 or a SYN3 homolog or analog. In the urinary bladder, as much as a 1,000 to 10,000 fold increase in interferon gene expression has been achieved by use of the combination of SYN3 with the recombinant adenoviral vector as compared to the use of the vector without SYN3.

Claims

1. A pharmaceutical composition comprising gene delivery enhancing agent selected from the group consisting of SYN3 and a SYN3 homolog;

and

a gene delivery system, wherein the gene delivery system contains a gene for interferon and wherein the gene for interferon is operably linked to a genetic regulatory element which modulates expression of the gene.

2. The pharmaceutical composition of claim 1, wherein the composition comprises a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 1, wherein the composition is lyophilized.

4. The pharmaceutical composition of claim 1, wherein the agent is SYN3.

5. The pharmaceutical composition of claim 1, wherein the interferon is selected from the group consisting of α

-interferon, β

-interferon interferon, δ

-interferon, γ

-interferon, and a fusion interferon thereof

6. The pharmaceutical composition of claim 1, wherein the interferon is selected from the group consisting of interferon α

-2b, a fusion interferon is α

-/2α

-1, and interferon α

-2e.

7. The pharmaceutical composition of claim 1, wherein the gene delivery system comprises a recombinant viral vector.

8. The pharmaceutical composition of claim 1, wherein the recombinant viral vector is selected from the group consisting of a herpes viral vector, retroviral vector, vaccinia viral vector, and an adenoviral vector.

9. The pharmaceutical composition of claim 1, wherein the agent is SYN3, the interferon is human α

interferon or a fusion interferon thereof, and the gene delivery system is a recombinant adenoviral gene delivery system.

10. The pharmaceutical composition of claim 9, wherein the α

interferon is an α

₁ interferon or an α

₂ interferon.

11. The pharmaceutical composition of claim 1, wherein the interferon is human interferon.

12. The pharmaceutical composition of claim 1, wherein the composition is in unit dosage format and contains a therapeutic amount of the composition in which the amount of the agent is from 1 to 2000 mg.

13. The pharmaceutical composition of claim 1, wherein the homolog is a compound of the following formula:

14. The composition of claim 13, wherein R¹ and R² are both hydroxyl groups.

17. The composition of claim 13, wherein R⁴ is hydrogen;

and R⁵ is a member selected from the group consisting of a hydrogen, a saccharide residue, an optionally substituted alkyl, an optionally substituted acyl, and an optionally substituted acyloxy.

18. The composition of claim 13, wherein said compound has Formula III:

19. The compound of claim 13, wherein R⁴ is succinyl.

20. The compound of claim 13, wherein R⁴ is acetyl.

21. The compound of claim 13, wherein R³ is a trimethylammonium salt.

22. The compound of claim 13, wherein R³ is a triethylammonium salt.

50. The method of claim 1, wherein the homolog has a formula:

15. The composition of 13, wherein m and n are each 1.

16. The composition of claim 15, wherein said compound has Formula II:

23. A method for delivering interferon gene therapy to a mammalian subject, said method comprising administering to the epithelial tissue or organ of the subject a therapeutically effective amount of a pharmaceutical composition comprising a gene delivery system wherein the gene for interferon is operably linked to a genetic regulatory element that modulates expression of the interferon gene and an agent selected from the group consisting of SYN3 and SYN3 homologues;

wherein the agent enhances the delivery of the interferon gene to the tissue or organ.

24. The method of claim 23, wherein the agent is SYN3.

25. The method of claim 23, wherein the agent is SYN3 and the concentration of the SYN3 in the composition is from 0.1 mg to 10 mg/ml.

26. The method of claim 25, wherein the interferon is selected from the group consisting of α

-interferon, β

-interferon interferon, δ

-interferon, γ

-interferon, and a fusion interferon thereof.

27. A method of claim 26, wherein the interferon is selected from the group consisting of interferon α

-2b, a fusion interferon is α

-/2α

-1, and interferon α

-2e.

28. The method of claim 23, wherein the gene delivery system comprises a recombinant viral vector.

29. The method of claim 28, wherein the recombinant viral vector is selected from the group consisting of a herpes viral vector, retroviral vector, vaccinia viral vector, and an adenoviral vector.

30. The method of claim 23, wherein the gene delivery system comprises DNA and a cationic lipid.

31. The method of claim 23, wherein the subject is human, the agent is SYN3, the interferon is human α

interferon or a fusion interferon thereof, and the gene delivery system is a recombinant adenoviral gene delivery system.

32. The method of claim 25, wherein the α

interferon is an α

₁ interferon or an α

₂ interferon.

33. The method of claim 23, wherein the interferon is human interferon.

34. The method of claim 23, wherein the composition is administered intravesically to the tissue or organ.

35. The method of claim 23, wherein the tissue or organ is cancerous.

36. The method of claim 35, wherein the tissue or organ is the human urinary bladder.

37. The method of claim 36, wherein the administering is at intervals selected from the group consisting of about once a week, twice a month, monthly, and bi-monthly.

38. The method of claim 36, wherein the administering is modulated with respect to frequency or the amount of the composition administered to maintain the expression of the interferon gene within a predetermined range.

39. The method of claim 36, wherein the urine is monitored to determine expression of the interferon.

40. The method of claim 36, wherein composition is administered in a volume from about 50 to 600 ml.

41. The method of claim 40, wherein the volume is from about 100 to 300 ml.

42. The method of claim 36, wherein the composition is administered by catheter.

43. The method of claim 36, wherein the catheter is a balloon catheter and the balloon portion of the catheter is inflated after insertion to reduce the void volume of the bladder.

44. The method of claim 36, wherein the subject is a relapsed or recurrent cancer patient.

45. The method of claim 44, wherein the subject was previously treated with BCG therapy.

46. The method of claim 23, wherein the tissue or organ is an airway tissue or organ, a upper or lower gastrointestinal tissue or organ, or a peritioneal tissue or organ.

47. The method of claim 46, wherein the tissue or organ is selected from the group consisting of the upper or lower airways, the lung, the nasal sinuses, the mouth, the esophagus, the stomach, the intestines, the colon, the uterus, the cervix, and the ovaries.

48. The method of claim 47, wherein the composition is administered over a period from about 5 minutes to about 2 hours.

49. The method of claim 23, wherein the concentration of SYN3 in the composition is in an amount from 0.1 to 10 mg/ml.

51. A kit comprising:

a first container containing SYN3 or a SYN3 homologue capable of enhancing the delivery of a gene delivery system; and

a second container containing the gene delivery system wherein the gene delivery system has an interferon gene operably linked to a genetic regulatory element modulating the expression of the interferon gene.

52. The kit of claim 51, wherein the first container contains a lyophilized formulation of SYN3.

53. The kit of claim 51, wherein the second container contains a lyophilized formulation of the gene delivery system.

54. The kit of claim 52, wherein the second container contains a lyophilized formulation of the gene delivery system.

55. The kit of claim 54, wherein the gene delivery system is a recombinant adenoviral vector.

56. The kit of claim 54, wherein the interferon gene is an α

-interferon gene.

57. The kit of claim 56, wherein the interferon gene is human.

58. The kit of claim 51, wherein the homolog satisfies the following formula: